Personalized Cancer Treatment Offers New Hope to Patients Facing Stage Four Diagnoses
Table of Contents
A revolutionary approach to cancer treatment, focusing on the genetic makeup of tumors rather than their origin, is offering a lifeline to patients like Graham Caveney, who was initially given just over a year to live after a stage-four oesophageal cancer diagnosis in 2022. The innovative strategy, pioneered at The Christie hospital in Manchester, is demonstrating remarkable success in stabilizing and even shrinking tumors, offering a potential paradigm shift in oncology.
From Misdiagnosis to a Devastating Prognosis
For months, 61-year-old Graham Caveney suffered with a burning sensation in his throat, leading to repeated visits to the emergency room. Though, his symptoms were consistently attributed to ulcers or acid reflux – a common condition where stomach acid flows back into the oesophagus. By the time a correct diagnosis of oesophageal cancer was made, the disease had already spread to his liver and lymph nodes, significantly reducing treatment options.
“I was told that I could have only a year to live, which was devastating,” Caveney recounts. Initial standard treatment provided temporary relief, but by late 2024, it ceased to be effective, leaving him facing palliative care.
A Trial Offering a New Lease on Life
Facing limited options, Caveney was offered a place on an early-stage clinical trial testing a novel combination of cancer drugs. Within months of starting the treatment, the size of his tumor was halved, and his condition stabilized. “I have been able to live the last few years pain-free,” Caveney shares. “It has given me a new lease of life – I feel
fortunate to have been given this opportunity.” The trial, known as Petra, utilizes the drug capivasertib 5305, designed to selectively target the protein within cancer cells.
Unlike conventional trials focused on specific cancer types like breast, prostate, or lung, the Petra trial targets specific DNA changes, irrespective of origin. In Caveney’s case, the treatment focused on an overproduction of the HER2 gene, commonly found in both breast and oesophageal cancers. Dr. Weaver notes that this genetic fault is present in other tumors as well,though it is not routinely tested for. The drug combination has also demonstrated positive results in treating breast cancer.
Success Stories beyond oesophageal Cancer
Elaine Sleigh, a 42-year-old mother of one, was diagnosed with an aggressive form of breast cancer in 2022 that recurred three times and spread to her lymph nodes. After less than a year on the Petra trial, her tumors shrank by 65 percent. “I’ve now had six cycles [of treatment], and with each one I get stronger and closer to my normal self,” she stated.
.
A Future of Personalized Oncology
The research team believes this approach could become the standard of care. “What is vital going forward, though, is the approach itself,” Dr.Weaver emphasizes. “At The Christie we are now running a number of trials across a dozen different tumour types,and different drug combinations,focusing on the genes causing the growth. The hope is this becomes the standard approach to care over the next decade – it is really exciting.” Experts also highlight the potential for fewer side effects and improved quality of life for patients.
While Caveney had to withdraw from the trial due to a rare complication – difficulty breathing – his medical team remains optimistic about the impact of the treatment. “We have seen a significant reduction in Graham’s tumour,his condition has stabilised and we may now be able to offer further treatment if the tumour starts to grow again,” Dr. Weaver confirms.
Caveney himself remains hopeful.”When I was younger, the word cancer was saeid in hushed tones,” he reflects. “But now, thanks to advances in treatment, more and more people like me are living well with and beyond cancer.”
It’s important to note that around one in four cancers are diagnosed at stage four, meaning the disease has already spread to another part of the body.
